Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Stresses Stability In Settling Oklahoma Opioids Case

Executive Summary

Teva says paying $85m to settle claims it contributed to opioid abuse in Oklahoma is important in maintaining the stability of the heavily indebted group.

You may also be interested in...



Teva Settles With San Francisco But New York Could Be Set To Prize Open Old Wounds

Teva has settled the final outstanding advanced US state-level opioid-related case against the firm, but recent allegations from the New York attorney general could see the firm back in court sooner rather than later.

Teva Settles Opioid Litigation In Florida For $177m

Teva has settled the opioid claims it faced in the state of Florida, alongside CVS, Allergan and Endo.

Teva Settles Rhode Island Opioid Claims, Seeks Nationwide Agreement

Teva has settled with the state of Rhode Island on opioid-related claims and is set to pay the state $21m in cash and provide $78.5m worth of Narcan and Suboxone. The settlement was reached just as Rhode Island was preparing to take Teva to trial.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB140361

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel